These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 19421148)

  • 1. Proteolytic cleavages give receptor tyrosine kinases the gift of ubiquity.
    Ancot F; Foveau B; Lefebvre J; Leroy C; Tulasne D
    Oncogene; 2009 Jun; 28(22):2185-95. PubMed ID: 19421148
    [No Abstract]   [Full Text] [Related]  

  • 2. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
    Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
    Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
    Oliveira MN; Hemerly JP; Bastos AU; Tamanaha R; Latini FR; Camacho CP; Impellizzeri A; Maciel RM; Cerutti JM
    Thyroid; 2011 Sep; 21(9):975-85. PubMed ID: 21834681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma.
    Gujral TS; van Veelen W; Richardson DS; Myers SM; Meens JA; Acton DS; Duñach M; Elliott BE; Höppener JW; Mulligan LM
    Cancer Res; 2008 Mar; 68(5):1338-46. PubMed ID: 18316596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Creation and characterization of a doxycycline-inducible mouse model of thyroid-targeted RET/PTC1 oncogene and luciferase reporter gene coexpression.
    Knostman KA; Venkateswaran A; Zimmerman B; Capen CC; Jhiang SM
    Thyroid; 2007 Dec; 17(12):1181-8. PubMed ID: 18004977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SH2B1beta adaptor is a key enhancer of RET tyrosine kinase signaling.
    Donatello S; Fiorino A; Degl'Innocenti D; Alberti L; Miranda C; Gorla L; Bongarzone I; Rizzetti MG; Pierotti MA; Borrello MG
    Oncogene; 2007 Oct; 26(45):6546-59. PubMed ID: 17471236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysfunction of the RET receptor in human cancer.
    Santoro M; Carlomagno F; Melillo RM; Fusco A
    Cell Mol Life Sci; 2004 Dec; 61(23):2954-64. PubMed ID: 15583857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A redox-linked novel pathway for arsenic-mediated RET tyrosine kinase activation.
    Kato M; Takeda K; Hossain K; Thang ND; Kaneko Y; Kumasaka M; Yamanoshita O; Uemura N; Takahashi M; Ohgami N; Kawamoto Y
    J Cell Biochem; 2010 May; 110(2):399-407. PubMed ID: 20235151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases.
    Jung HS; Kim DW; Jo YS; Chung HK; Song JH; Park JS; Park KC; Park SH; Hwang JH; Jo KW; Shong M
    Mol Endocrinol; 2005 Nov; 19(11):2748-59. PubMed ID: 15994200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.
    Boulay A; Breuleux M; Stephan C; Fux C; Brisken C; Fiche M; Wartmann M; Stumm M; Lane HA; Hynes NE
    Cancer Res; 2008 May; 68(10):3743-51. PubMed ID: 18483257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Another piece of the p27Kip1 puzzle.
    Kaldis P
    Cell; 2007 Jan; 128(2):241-4. PubMed ID: 17254963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of RET tyrosine kinase by SU5416.
    Mologni L; Sala E; Cazzaniga S; Rostagno R; Kuoni T; Puttini M; Bain J; Cleris L; Redaelli S; Riva B; Formelli F; Scapozza L; Gambacorti-Passerini C
    J Mol Endocrinol; 2006 Oct; 37(2):199-212. PubMed ID: 17032739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.
    Borrello MG; Aiello A; Peissel B; Rizzetti MG; Mondellini P; Degl'Innocenti D; Catalano V; Gobbo M; Collini P; Bongarzone I; Pierotti MA; Greco A; Seregni E
    Endocr Relat Cancer; 2011 Aug; 18(4):519-27. PubMed ID: 21690267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC).
    Kim DW; Chung HK; Park KC; Hwang JH; Jo YS; Chung J; Kalvakolanu DV; Resta N; Shong M
    Mol Endocrinol; 2007 Dec; 21(12):3039-49. PubMed ID: 17761947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
    Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
    Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mouse soluble GFRalpha4 receptor activates RET independently of its ligand persephin.
    Yang J; Runeberg-Roos P; Leppänen VM; Saarma M
    Oncogene; 2007 May; 26(26):3892-8. PubMed ID: 17213820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
    Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
    J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RET proto-oncogene: a potential target for molecular cancer therapy.
    Pützer BM; Drosten M
    Trends Mol Med; 2004 Jul; 10(7):351-7. PubMed ID: 15242684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.